Iktos’ mission

We aim to accelerate the discovery of effective treatments, advancing global health by delivering new solutions to patients faster and more reliably. To achieve this, we combine generative AI and robotics to tackle the inefficiencies of traditional drug development processes.

As innovators, we envision a future where drug discovery teams deliver breakthrough drug candidates at unprecedented speed, enabled by the seamless integration of every step in the Design-Make-Test-Analyze cycle.

milestones and achievements

A Track Record of Success

From our founding in 2016 to the present, Iktos has achieved key milestones :

2016

Founding of Iktos

2018

First successful pharma collaborations

2019

Launch of generative AI platform (Makya)

2020

Launch of retrosynthesis AI platform (Spaya)

2023

Series A 15.5M€
Initiation of in-house drug discovery

2024

Launch of our Integrated Drug Discovery platform, including Spaya, Makya and Robotics
Acquisition of Synsight

backgroundbackground

Meet our Team

Meet the dedicated team behind Iktos’s success, comprising industry-leading experts in AI, robotics, and pharmaceutical sciences.

founders and board

MS Ecole Polytechnique Paris and AgroParisTech. 20+ years experience in pharma R&D, strategic consulting and entrepreneurship in biotech.

Co-founder and CEO, Yann leads the development of Iktos with his knowledge of the pharmaceutical industry and a broad understanding of methods, approaches and tools of data science.

Yann Gaston-MathéCo-Founder & CEO | Board member
Yann Gaston-Mathé
Yann Gaston-MathéCo-Founder & CEO | Board member

PhD in organometallic chemistry from University of Geneva. Medicinal chemist, skilled data scientist.

Co-founder and CSO, Quentin plays a key role in the strategic steering of Iktos’s R&D and portfolio development and supervision of project delivery for partners and customers.

Quentin PerronCo-Founder & CSO | Board Observer
Quentin Perron
Quentin PerronCo-Founder & CSO | Board Observer

PhD in Artificial Intelligence. Several years experience in software development and R&D. Contributed to the emerging data science field by creating distributed computation platform for Big Data processing.

Co-founder and CTO at Iktos, Nicolas leads the technological developments of the company.

Nicolas Do HuuCo-Founder & CTO | Board Member
Nicolas Do Huu
Nicolas Do HuuCo-Founder & CTO | Board Member

MBA from New York University (Sterne School of Business) and PhD in organic chemistry from MIT, USA.

He brings an exceptional professional background with unvaluable experience in pharmaceutical research, investment and company leadership. He is the author of numerous publications in prestigious scientific journals and has filed over 20 patents during his career.

Roman also serves as Chairman of HDAX Therapeutics, and a Board Member at ReColony.

Roman FleckChairman of the Board
Roman Fleck
Roman FleckChairman of the Board

Ph.D. in Pharmaceutical Sciences from the University of Lausanne, Switzerland.

Bertrand is the CEO of Debiopharm and Senior Vice-Chairman of the Life Science activities of Après-demain. His work in various roles has contributed to two blockbuster therapies for cancer patients, oxaliplatin and triptorelin, along with a potential 3rd blockbuster drug currently in phase III research in Head & Neck cancer with an international partner.

Bertrand DucreyBoard Member
Bertrand Ducrey
Bertrand DucreyBoard Member

Ph.D. in Biochemistry and Molecular Genetics from the University of Oxford.

Nadiya joined M Ventures Biotechnology team covering Healthcare and Life Sciences investments as an Associate in 2021. She has strong experience in strategy and transformation for corporate healthcare clients, health systems, providers, pharma and digital health clients in EMEA, Asia Pacific and Emerging Markets.

Nadiya IshnazarovaBoard Member
Nadiya Ishnazarova
Nadiya IshnazarovaBoard Member

Engineering degree from CentraleSupélec and a Master of Science in Finance from the Imperial College (UK).

Fabien joined Omnes’s Investment Team in January 2017 and was appointed Director in 2021. He actively invests in TechBio and Deeptech companies and sits at the supervisory board of companies such as SeqOne Genomics, Qubit Pharmaceuticals, Quandela, Sekoia.io.

Fabien CollangettesBoard Observer
Fabien Collangettes
Fabien CollangettesBoard Observer

MBA from Mannheim Business School, Germany, and a Diploma in Computer Science and Business Administration (Business Informatics) from Cooperative State University Karlsruhe, Germany.

Christian joined M Ventures in August 2019 as Head of Strategy and currently serves as a Principal in the Biotechnology team. Prior to joining M Ventures, Christian worked at Merck KGaA, where he focused on impactful strategy-related projects across all business sectors of the Merck Group.

Christian UhrichBoard Observer
Christian Uhrich
Christian UhrichBoard Observer

Ph.D. in Chemistry from Stanford University. 25+ years of professional experience in drug discovery and scientific leadership in the pharma industry.

Vincent is the co-inventor of several new antibacterials and oncology drugs put in clinical development. Co-author of more than 50 publications and patent applications, he currently serves as Head of Medicinal Chemistry at Debiopharm.

Vincent GeruszBoard Observer
Vincent Gerusz
Vincent GeruszBoard Observer

Graduated from Lausanne Hospitality Management school

Jérôme joined the Private Equity investment company MI3 S.A. in Luxembourg in 2014, where he operates as Investment Manager and Director. Previously, he was the Chief Financial Officer for the Belgian startup Rouge Tomate in Brusselles and New York and then Management Controller for the Groupe Castel in West Africa.

Jérôme DhamelincourtBoard Observer
Jérôme Dhamelincourt
Jérôme DhamelincourtBoard Observer

scientific advisory board

Rafael Gomez-Bombarelli is the Paul M. Cook Career Development Professor at MIT, leading the Learning Matter Lab. He holds a degree in chemistry from Universidad de Salamanca, followed by postdoctoral work at Heriot-Watt and Harvard Universities. His multiple accolades include the Sloan Fellowship, the Camille and Henry Dreyfus Foundation "Machine Learning in the Chemical Sciences and Engineering Award," and the Google Faculty Research Award. He co-founded Calculario, a Harvard spinout, and is former Chief Learning Officer at ZebiAI.

Rafael Gomez-Bombarelli, PhD.Innovator in AI-Driven molecular design. Paul M. Cook Career Development Professor at MIT’s Department of Materials Science and Engineering
Scientific Advisory Board
Rafael Gomez-Bombarelli, PhD.Innovator in AI-Driven molecular design. Paul M. Cook Career Development Professor at MIT’s Department of Materials Science and Engineering

Thierry Masquelin is renowned for creating the Lilly Life Science Studio (L2S2) and the world’s first Automated Synthesis and Purification Lab (ASPL). He has a PhD from the University of Haute Alsace and currently serves as COO of the ASPIRE initiative at the National Center for Advancing Translational Sciences (NCATS). After holding senior positions at Lilly, he joined Recursion Therapeutics as Senior Director, to develop a unified, multi-disciplinary platform to consolidate early drug discovery phases.

Thierry Masquelin, PhD.Visionary leader in chemistry and testing automation technology. Former Senior Director, Medicinal Chemistry & Technology at Recursion, COO ASPIRE at NIH
Scientific Advisory Board Member
Thierry Masquelin, PhD.Visionary leader in chemistry and testing automation technology. Former Senior Director, Medicinal Chemistry & Technology at Recursion, COO ASPIRE at NIH

Laurent Debussche served as VP Global Head of Oncology Research at Sanofi, where he advanced several first-in-human oncology drug candidates. He has co-authored over 60 international scientific publications and holds several dozen patents. With a PhD in Molecular Biology from Pierre et Marie Curie University (France), Laurent has led innovative research initiatives throughout his career.

Laurent Debussche, PhD.Senior R&D expert in first-in-human drug discovery. Former Vice President Oncology Research at Sanofi CEO at DLog Consulting
Scientific Advisory Board Member
Laurent Debussche, PhD.Senior R&D expert in first-in-human drug discovery. Former Vice President Oncology Research at Sanofi CEO at DLog Consulting

Friedrich Rippmann is former Director of Computational Chemistry and Biologics at Merck KGaA. A very early and visionary adopter of AI in the Pharmaceutical industry, he led the integration of AI and machine learning into drug discovery and contributed to the advancement of AI methodology. His groundbreaking efforts in discovering and optimizing lead compounds have revolutionized the application of computational chemistry in Pharma. Currently, he is an independent AI consultant and serves as Director at Combinable.ai.

Friedrich Rippmann, PhD.Computational chemistry expert and AI drug discovery leader. Former Director of Computational Chemistry and Biologics at Merck. Independent AI consultant and Director at Combinable.ai
Scientific Advisory Board Member
Friedrich Rippmann, PhD.Computational chemistry expert and AI drug discovery leader. Former Director of Computational Chemistry and Biologics at Merck. Independent AI consultant and Director at Combinable.ai

Dominique Bridon is a seasoned pharmaceutical executive, with expertise spanning oncology, infectious diseases, metabolic, and cardiovascular disorders, Dr. Bridon has been instrumental in developing successful and innovative therapies across multiple areas. Holding senior management positions, including Abbott Laboratories, Ipsen, and Epivax Oncology, as well as several biotechs successfully acquired by larger players, such as Optivia, Enobia, and Syntaxin. Additionally, Dr. Bridon co-founded Conjuchem, which achieved an IPO on the Toronto Stock Exchange and was later acquired.

Dominique Bridon, PhD.Pharma-Biotech executive and drug development expert. Executive Chairman at Sybilla Therapeutics, CSO at EvextaBio
Scientific Advisory Board Member
Dominique Bridon, PhD.Pharma-Biotech executive and drug development expert. Executive Chairman at Sybilla Therapeutics, CSO at EvextaBio

executive committee

PhD in organic chemistry, +30 years of experience in Drug Discovery and Medicinal Chemistry.

Alexis contributed to the successful discovery and development of >15 clinical candidates going to Phase I and beyond. Now SVP, Head of Drug Discovery at Iktos.

Alexis DenisSVP, Head of Drug Discovery
Alexis Denis
Alexis DenisSVP, Head of Drug Discovery

PhD in Chemistry, +18 years of experience in drug discovery portfolio strategy and management and business development at Novartis.

Formerly VP, and Head of Business Development at Chinook Therapeutics, overseeing all business development aspects until its acquisition by Novartis AG in August 2023. Now, at Iktos, leading the global business development team and contributing to the company’s strategy as a member of the executive committee.

Avirup BoseChief Business Officer
Avirup Bose
Avirup BoseChief Business Officer

Engineering degree from Ecole Polytechnique and Master’s in Applied Biosciences & Biotechnology from Imperial College London. In charge of strategic planning & corporate development at Iktos.

Marion LaguetteDirector, Strategic Planning, Corporate Development and Operations
Marion Laguette
Marion LaguetteDirector, Strategic Planning, Corporate Development and Operations

MANAGEMENT TEAM

MS in Materials Sciences & Engineering from Université de Montpellier and MBA in Marketing from Indiana University’s Kelley School of Business. More than 30 years of sales, and business development activities, including more than ten years of successful partnerships with pharmaceutical industries worldwide. Now VP-Head of BD, Sales & Operations, USA

Philip LautVP, Head of US Operations, Sales & Business Development
Philip Laut
Philip LautVP, Head of US Operations, Sales & Business Development

PhD in Pharmaceutical Sciences. 13 years experience in pharma R&D at Astellas Pharma as an expert in computational chemistry and chemoinformatics. Now, Representative Director of Iktos K.K., VP Japan Operations and Business Development at Iktos, leading Iktos’s business expansion in APAC region.

Hideyoshi FujiVP, Japan Operations and Business Development
Hideyoshi Fuji
Hideyoshi FujiVP, Japan Operations and Business Development

PhD in organic chemistry. Research Associate at the University of Cambridge. Senior Research Scientist at Idenix Pharmaceuticals. Co-founder and Medicinal Chemistry Director at Oxeltis. 20 years of experience in the pharmaceutical industry. Now, Head of Robotics, Iktos.

Jean Christophe MeillonHead of Robotics Lab
Jean Christophe Meillon
Jean Christophe MeillonHead of Robotics Lab

PhD and post-doc in Bioinformatics. Spearheaded the development of Iktos structure-based generative modeling technology and pipeline. Head of Iktos modeling team.

Brice HoffmannHead of Computational Chemistry
Brice Hoffmann
Brice HoffmannHead of Computational Chemistry

Master’s in Applied Mathematics and Computer Science. Key contributor to the development of Iktos generative modeling technology. Lead developer of Iktos retrosynthesis technology.

Hamza TajmouatiHead of AI Research and Data Science
Hamza Tajmouati
Hamza TajmouatiHead of AI Research and Data Science

Master’s in Software Engineering. 15 years experience as CTO, successful experience of software product development. In charge of the software development team.

Abderraouf El GasserHead of Platform Development
Abderraouf El Gasser
Abderraouf El GasserHead of Platform Development

PhD in chemistry. Over 12 years of experience of medicinal chemistry. Project leader in a med chem project that successfully delivered a drug candidate. Now leads the Med Chem team at Iktos.

Christopher HoussemanHead of Medicinal Chemistry
Christopher Housseman
Christopher HoussemanHead of Medicinal Chemistry

Pharmacist and PhD in computational structural biology from the University of Strasbourg. In charge of business development activities in Europe

Nicolas MartinHead of business development Europe
Nicolas Martin
Nicolas MartinHead of business development Europe

Engineering degree from Ecole polytechnique and MSc at Polytechnique Montreal in Biomedical. In charge of the design and development of data processing pipelines and High performance computing systems for computational chemistry.

Grégoire GermainHead of Data engineering and HPC
Grégoire Germain
Grégoire GermainHead of Data engineering and HPC

Master's degree in IT system expertise. Former developer and infrastructure engineer. In charge of Cloud engineering team at Iktos.

Vincent PommierHead of Cloud engineering
Vincent Pommier
Vincent PommierHead of Cloud engineering

Engineering degree from Ecole Centrale Lyon and Master's degree in Health engineering from Université de Lyon. Spent 10+ years in pharma company as project manager, team manager and operational excellence lead. In charge of operational excellence, processes and transversal projects at Iktos.

Noa BerkovichManager, Operational Excellence
Noa Berkovich
Noa BerkovichManager, Operational Excellence

Meet us at :

Chem-Bio Informatics (CBI) Society Annual Meeting 2024
Funabori, Japan | 2024-10-28

Chem-Bio Informatics (CBI) Society Annual Meeting 2024

Learn more
EFMC - International Symposium on Medicinal Chemistry
Rome, Italy | 2024-09-01

EFMC - International Symposium on Medicinal Chemistry

Learn more
37th European Peptides Symposium
Florence, Italy | 2024-08-25

37th European Peptides Symposium

Learn more

Partner with Iktos

Embark with us

Since our inception in 2018, we have consistently delivered value through over 60 collaborations with leading pharmaceutical, biotech, and academic institutions. Our highly skilled team is dedicated to pushing the boundaries of AI-driven drug design, making us a trusted partner in your molecular odyssey.

Get Started Today

Explore how Iktos’s groundbreaking solutions can accelerate your drug discovery projects. Contact us to learn more and request a demo of our platforms.

Get Started Today

recent Articles about iktos

Iktos appoints new Scientific Advisory Board
10.17.2024

Iktos appoints new Scientific Advisory Board

Iktos announces the acquisition of Synsight
07.08.2024

Iktos announces the acquisition of Synsight

Iktos announces the appointment of Roman Fleck as Chairman
05.02.2024

Iktos announces the appointment of Roman Fleck as Chairman